A new cell therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of prostate cancer that has spread and is no longer controlled by hormone therapy (castration-resistant).
- Your PSA level has to be at least 1 ng/mL, and your cancer must have shown signs of getting worse in the last 6 months on scans or PSA tests.
- You must have already tried at least one type of hormone therapy (like abiraterone or enzalutamide) and a chemotherapy (like docetaxel) for your cancer.
- You should be able to do your daily activities without major help (ECOG score 0 or 1).
- You cannot have untreated brain metastases, an active autoimmune disease, or certain heart conditions like uncontrolled arrhythmias.
- You must be willing to provide a tumor sample (biopsy) from before and after treatment, if it’s safe to do so.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This study tests a new radioactive drug, [225Ac]-AZD2284, for men with prostate cancer that has spread and no longer responds to hormone therapy. The drug is designed to target cancer cells and deliver radiation directly to them, potentially slowing the cancer's growth.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.